Location of Centers Participating in the CIBMTR 2015 Annual Number of Transplant Recipients in the US by Transplant Type Allogeneic Transplant Recipients in the US by Donor Type Cumulative Plot of Transplant Recipients in the US by Transplant Type ID: 740023
Download Presentation The PPT/PDF document "Current Uses and Outcomes of Hematopoiet..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Current Uses and Outcomes of Hematopoietic Stem Cell TransplantationSlide2
Location of Centers Participatingin the CIBMTR 2015Slide3
Annual Number of Transplant Recipients in the US by Transplant TypeSlide4
Allogeneic Transplant Recipients in the US, by Donor TypeSlide5
Cumulative Plot of Transplant Recipients in the US by Transplant TypeSlide6
HLA-Match Sibling Donor Allogeneic Transplants in Patients ≤20 YearsSlide7
Unrelated Donor Allogeneic Transplants in Patients ≤20 YearsSlide8
HLA-Match Sibling Donor Allogeneic Transplants in Patients Age >20 yearsSlide9
Unrelated Donor Allogeneic Transplants in Patients Age >20 yearsSlide10
Trends in Autologous Transplants by Recipient Age*Slide11
Trends in Allogeneic Transplants by Recipient Age*Slide12
Indications for Hematopoietic Stem Cell Transplants in the US, 2013Slide13
Causes of Death after Autologous Transplants done in 2012-2013Slide14
Causes of Death after HLA Match Sibling Transplants done in 2012-2013Slide15
Causes of Death after Unrelated Donor Transplants done in 2012-2013Slide16
Allogeneic Transplants Registered with the CIBMTRSlide17
Survival after HLA Match Sibling Donor Transplants for AML, 2003-2013Slide18
Survival after Unrelated Donor Transplants for AML, 2003-2013Slide19
Survival after HLA Match Sibling Donor Transplants for AML, Age <20 Years, 2003-2013Slide20
Survival after Allogeneic Transplants for Myelodysplastic Syndrome (MDS), 2003-2013Slide21
Survival after Allogeneic Transplants for Myelodysplastic Syndrome (MDS), 2003-2013Slide22
Survival after HLA Match Sibling Donor Transplants for Myeloproliferative Diseases, 2003-2013Slide23
Survival after Unrelated Donor Transplants for
Myeloproliferative Diseases
, 2003-2013Slide24
Survival after HLA Match Sibling Donor Transplants for ALL, Age <20 Years, 2003-2013Slide25
Survival after Unrelated Donor Transplants for ALL, Age <20 years, 2003-2013Slide26
Survival after HLA Match Sibling Donor Transplants for ALL, Age ≥20 Years, 2003-2013Slide27
Survival after Unrelated Donor Transplants for ALL, ≥20 Years, 2003-2013Slide28
Survival after HLA Match Sibling Transplants for CML, 2003-2013Slide29
Survival after Allogeneic Transplants for Chronic Lymphocytic Leukemia (CLL), 2003-2013Slide30
Survival after Allogeneic Transplants for Severe Aplastic Anemia, <20 Years, 2003-2013Slide31
Survival after Allogeneic Transplants for Severe Aplastic Anemia, ≥20 Years, 2003-2013Slide32
Survival after Autologous Transplants for Hodgkin Lymphoma, 2003-2013Slide33
Survival after Allogeneic Transplants for Hodgkin Lymphoma, 2003-2013Slide34
Survival after Autologous Transplants for Follicular Lymphoma, 2003-2013Slide35
Survival after Allogeneic Transplants for Follicular Lymphoma, 2003-2013Slide36
Survival after Autologous Transplants for Diffuse Large B-cell Lymphoma (DLBCL), 2003-2013Slide37
Survival after HLA Match Sibling Transplants for Diffuse Large B-cell Lymphoma (DLBCL)
, 2003-2013Slide38
Survival after Transplants for Mantle Cell Lymphoma, 2003-2013Slide39
Survival after Transplants for Multiple Myeloma, 2003-2013Slide40
Survival after Autologous Transplants for Multiple Myeloma, 2000-2013